Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Value

<< Previous

Bullboard Posts

Next >>

Post by Doccoleon May 07, 2021 2:19pm

261 Views

Post# 33153708

Value

We have the share count.
we have the cash to allegedly take us through phase 3.
We have a pipeline.
we have full integration.
we have a deal made.

hopefully analyst will shed light on value of company.

based on what we know- does anyone have any resource or fact of what the company is worth? We should be trading at with a MC 600, still very under valued.

Trying to find the last piece to determine legit expectations.

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program